Steps Following Attainment of Remission: Discontinuation of Antidepressant
Open accessAbstract
Depressive disorders require long-term treatment with antidepressants, psychotherapy, or both. The goal of antidepressant therapy is complete remission of symptoms and return to normal daily functioning. Studies have shown that achieving remission and continuing antidepressant therapy long after the acute symptoms remit can protect against the relapse or recurrence of the psychiatric episode. Many patients, however, inadvertently or intentionally skip doses of their antidepressant, and even discontinue it, if their symptoms improve or if they experience side effects. Antidepressant discontinuation may increase the risk of relapse or precipitate certain distressing symptoms such as gastrointestinal complaints, dizziness, flu-like symptoms, equilibrium disturbances, and sleep disorders. Documented with all classes of antidepressants, these reactions may emerge within a couple of days, or even hours, after the abrupt discontinuation of an antidepressant with a short half-life. These distressing responses may be mistaken for a relapse or recurrence. It is important to recognize the potential for these sequelae and educate patients about the need to take all antidepressants at the doses prescribed, warning them of the symptoms that may occur if they skip doses or stop their medication too quickly. Antidepressants should be tapered slowly over a period of days, weeks, or even months, depending on the dose, duration of treatment, and pharmacologic properties of the agent, as well as the patient's individual response. This article reviews the risks and reactions associated with discontinuation of antidepressants. It offers guidelines for distinguishing relapse and recurrence from discontinuation responses as well as for prevention and management of the antidepressant discontinuation syndrome.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The withdrawal syndrome can be differentiated from recurrence of the underlying disorder by its quickness of onset (days rather than weeks), rapid response to re-introduction of the antidepressant (generally within hours, certainly within days), and the presence of somatic and psychological symptoms quite distinct from the original illness.
“However, the withdrawal syndrome can be distinguished from a relapse or recurrence of the underlying disorder by its quickness of onset (days rather than weeks) 3,7,8 , rapid response to re-introduction of the antidepressant (generally within hours, certainly within days) 3,7,9 , and the presence of somatic and psychological symptoms quite distinct from the original illness (including, dizziness,”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [8]
Cites
Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review
Zajecka, J., Tracy, K. A., & Mitchell, S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0702 · Cited by 209 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280 · see citing works
Sartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B. M., Brand, U., Fleischhacker, W., Goodwin, G. M., Grunze, H., Knapp, M. R. J., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 98 · see citing works
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73 · see citing works
Anxiety: An ignored aspect of Parkinson's disease lacking attention.
Khatri, D., Choudhary, M., Sood, A., & Singh, S. B. (2020) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2020.110776 · Cited by 65 · see citing works
Goldstein-Piekarski, A. N., Korgaonkar, M., Green, E. M., Suppes, T., Schatzberg, A., Hastie, T., Nemeroff, C., & Williams, L. (2016) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1606671113 · Cited by 55 · see citing works
“Defining remission as requiring functional improvement and alleviation of symptoms (31), we tested the following hypotheses:”
MethodErritzøe, D., Barba, T., Greenway, K. T., Murphy, R., Martell, J., Giribaldi, B., Timmermann, C., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102799 · Cited by 63 · see citing works
Guidance for the discontinuation or switching of antidepressant therapies in adults
Ogle, N. R., & Akkerman, S. R. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190012467210 · Cited by 45 · see citing works
Use of Serotonergic Antidepressants and Bleeding Risk in Patients Undergoing Surgery
Jeong, B.-O., Kim, S., Kim, S., Kim, J., Shin, I., & Yoon, J. (2013) · Psychosomatics · doi:10.1016/j.psym.2013.08.011 · Cited by 50 · see citing works
The sense of stopping migraine prophylaxis
Al-Hassany, L., Lyons, H., Boucherie, D. M., Farham, F., Lange, K. S., Marschollek, K., Onan, D., Pensato, U., Storch, E., Torrente, A., et al. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01539-8 · Cited by 40 · see citing works
“These symptoms can resemble the original symptoms of depression potentially leading to a higher risk of not coping with drug discontinuation [33].”
BackgroundKroeze, Y., Peeters, D., Boulle, F., van den Hove, D. V. D., van Bokhoven, H., Zhou, H., & Homberg, J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.145 · Cited by 36 · see citing works
Erritzøe, D., Barba, T., Spriggs, M. J., Rosas, F. E., Nutt, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241237870 · Cited by 33 · see citing works
“These symptoms can be distinguished from a relapse of the original disorder by rapidity of onset (Bhat and Kennedy, 2017; Shelton, 2001; Warner et al., 2006), the presence of somatic symptoms like nausea, shock-like feelings, dizziness (Black et al., 2000; Warner et al., 2006) and rapid response by…”
BackgroundPredictors of premature discontinuation of treatment in multiple disease states
Nantz, E., Liu-Seifert, H., & Skljarevski, V. (2009) · Patient Preference and Adherence · doi:10.2147/ppa.s4633 · Cited by 29 · see citing works
“It has been shown that patients who discontinue prematurely are likely to experience relapse of symptoms and other undesirable effects.(1,2) The issue of patient attrition also impacts the analysis of clinical studies.”
BackgroundTender Points as Predictors of Distress and the Pharmacologic Management of Fibromyalgia Syndrome
Mccarberg, B., Barkin, R., Wright, J. A., Cronan, T., Groessl, E., & Schmidt, S. (2003) · American Journal of Therapeutics · doi:10.1097/00045391-200305000-00005 · Cited by 25 · see citing works
An Active Inference Approach to Dissecting Reasons for Non-Adherence to AntidepressantsPreprint
Smith, R., Khalsa, S., & Paulus, M. (2019) · bioRxiv · doi:10.1101/743542 · Cited by 23 · see citing works
Asghar, J., Tabasam, M., Althobaiti, M. M., Ashour, A. A., Aleid, M. A., Khalaf, O. I., & Aldhyani, T. H. H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.873693 · Cited by 20 · see citing works
Tapering antidepressants: is 3 months slow enough?
Phelps, J. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.08.035 · Cited by 16 · see citing works
“Taper rate recommendations commonly range from no-taper for fluoxetine to three months for tricyclics, with the rest between 2–4 weeks [4], but these may be too fast.”
BackgroundDurgam, S., Gommoll, C., Migliore, R., Chen, C., Chang, C.-T., Aguirre, M., & Thase, M. E. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000236 · Cited by 16 · see citing works
“…with a greater risk of relapse include discontinuation of treatment too soon following initial response, multiple courses of acute antidepressant therapy, and residual symptoms and/or functional impairment after treatment (Shelton, 2001; Rush et al., 2006; Sheehan et al., 2011; Judd et al., 2015).”
BackgroundInfluentialChoi, H. N., Jung, D.-J., Jeon, Y.-H., & Kim, M. J. (2020) · The Arts in Psychotherapy · doi:10.1016/j.aip.2020.101689 · Cited by 17 · see citing works
Discontinuing antidepressants: Pearls and pitfalls
Zwiebel, S. J., & Viguera, A. C. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21020 · Cited by 17 · see citing works
Garcia, S., Schuh, M., Cheema, A., Atwal, H. K., & Atwal, P. (2017) · Case Reports in Genetics · doi:10.1155/2017/6236714 · Cited by 13
“Additional suggestions were given to gradually tapper down the patient from VEN based on recommendations published by Shelton [18].”
MethodUse of psychotropic drugs in dermatology: unique perspectives of a dermatologist and a psychiatrist.
Park, K. K., & Koo, J. (2013) · Clinical Dermatology · doi:10.1016/j.clindermatol.2011.11.013 · Cited by 13 · see citing works
Hitchcock, C., Rudokaite, J., Haag, C., Patel, S. D., Smith, A. J., Kuhn, I., Jermann, F., Ma, S. H., Kuyken, W., Williams, J., et al. (2021) · Behaviour Research and Therapy · doi:10.31234/osf.io/s98a6 · Cited by 11 · see citing works
“However, symptoms commonly recur when antidepressant medication is ceased (Shelton, 2001).”
BackgroundKroeze, Y., Peeters, D., Boulle, F., van den Hove, D. V. D., van Bokhoven, H., Zhou, H., & Homberg, J. (2015) · Translational Psychiatry · doi:10.1038/tp.2016.60 · Cited by 11 · see citing works
Akena, D. H., Okello, E. S., Simoni, J. M., & Wagner, G. J. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05301-7 · Cited by 10 · see citing works
Akena, D., Semeere, A., Kadama, P., Mwesiga, E., Nakku, J., & Nakasujja, N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268493 · Cited by 3 · see citing works
Depression Management During Cancer Treatment
Fulcher, C. (2006) · Oncology nursing forum · doi:10.1188/06.onf.33-35 · Cited by 3 · see citing works
Xia, T., Iles, R., Newnam, S., Lubman, D., & Collie, A. (2020) · Monash University Research Portal (Monash University) · doi:10.26180/13315952 · Cited by 2
Using Exercise To Treat Depression: An Analysis Of Clinical And Social Perspectives
Yeruva, H. (2019) · doi:10.26153/tsw/2522 · Cited by 2
Brand versus generic: addressing non-adherence, secular trends and non-overlap
Hunt, L., Murimi, I., Segal, J. B., Seamans, M. J., Scharfstein, D. O., & Varadhan, R. (2020) · Journal of the Royal Statistical Society. Series A, · doi:10.1111/rssa.12573 · Cited by 1
“Typically it takes 3 months for patients to respond to treatment, plus another 6 months of continuation for them to stabilize, so we would choose a follow-up period of 9 months during which to observe the therapeutic outcomes of interest (Shelton, 2001; Pringsheim et al., 2016).”
Brand vs. Generic: Addressing Non-Adherence, Secular Trends, and Non-Overlap
Hunt, L., Murimi, I., Segal, J. B., Seamans, M. J., Scharfstein, D. O., & Varadhan, R. (2019) · doi:10.48550/arxiv.1907.05385
“Are brand and generic drugs equivalent? And what does equivalent mean? Strom (1987) discusses three types of equivalence: chemical, biological, and therapeutic.”
BackgroundInfluentialAntidepressant Discontinuation Syndrome
Corbett, B., & Nordstrom, K. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-58260-3_45
Psychological and Physiological Influences on Multicultural and Nonverbal Assessment
McCallum, R., & McCallum, R. (2017) · doi:10.1007/978-3-319-50604-3_6
Characterization, treatment, and prevention of stress-induced psychopathology
Brachman, R. A. (2014) · doi:10.7916/d84b2zwq
Tricyclic Antidepressant Drug Interactions
Walterscheid, J. P., & Danielson, T. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-222-9_5
Lauderdale, S. (2009) · The American Pharmacists Association eBooks · doi:10.21019/9781582121055.ch70
- Authors
- Shelton, R. C.
- Affiliations
- Vanderbilt University Medical Center (US)
- Corresponding author
- Shelton, Richard C.
- ORCID
- Shelton, Richard C.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2001-08-01
- Volume
- 3
- Issue
- 4
- Pages
- 168-174
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- PMC
- PMC181183
- OpenAlex
- W2042510791
- Cited by
- 43
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 1 · 2013: 2 · 2012: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Sanofi
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- antidepressant discontinuation syndrome, antidepressant tapering, depression remission, relapse and recurrence, antidepressant discontinuation, dose skipping, withdrawal symptoms, patient education
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
